The Alderley Park Oncology Development Programme, a national programme co-funded by Innovate UK and supported by a collaboration of global big pharma and research institutions, has just been launched. This programme will find and develop start-up projects with the potential to improve the diagnosis and treatment of cancer.
Cancer researchers are invited to apply for a 3-day pre-accelerator bootcamp covering the basics of entrepreneurship, before 6-8 companies are chosen to progress to the 6-month intensive accelerator stage. Expertise and mentorship will be provided by a unique partnership of AstraZeneca, Johnson & Johnson Innovation, GlaxoSmithKline, Roche, The Christie NHS Foundation Trust, the Manchester Cancer Research Centre and Medicines Discovery Catapult, who will act as delivery partner for the programme. They will work closely with the researchers to help them develop fully validated, timed and costed project plans to improve their chances of attracting future investment.
Researchers will not only gain exposure from big pharma, but also the opportunity to receive up to £60k funding investment and lab/office space at Alderley Park – the UK’s largest single science campus.
Applications open on 23rd Nov, register your interest by clicking here.